pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
clindamycin pfizer 150 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 150 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 224.13 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
clindamycin pfizer 300 mg capsule rigide
pfizer ag - clindamycinum - capsule rigide - clindamycinum 300 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 283.27 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika
clindamycin pfizer granulato per la realizzazione di una soluzione orale
pfizer ag - clindamycinum - granulato per la realizzazione di una soluzione orale - clindamycinum 75 mg ut clindamycini-2 palmitatis hydrochloridum, simeticonum, poloxamerum 188, saccharum 1.8 g, aromatica (kirschen), e 214 0.6 mg ad granulatum corresp. solutio reconstituta 5 ml. - malattie infettive - synthetika
octreotide pfizer
pfizer italia s.r.l. - octreotide - octreotide
voriconazolo pfizer
pfizer italia s.r.l. - voriconazolo - voriconazolo
remifentanil pfizer
pfizer italia s.r.l. - remifentanil - remifentanil
latanoprost pfizer
pfizer italia s.r.l. - latanoprost - latanoprost
valsartan pfizer
pfizer italia s.r.l. - valsartan - valsartan
montelukast pfizer italia
pfizer italia s.r.l. - montelukast - montelukast